OBJECTIVEdIt is unclear whether people with and without diabetes equally benefitted from reductions in cardiovascular disease (CVD). We aimed to compare recent trends in hospital admission rates for angina, acute myocardial infarction (AMI), stroke, percutaneous coronary intervention (PCI), and coronary artery bypass graft (CABG) among people with and without diabetes in England. People with and without diabetes experienced similar proportional changes for all outcomes, with no significant differences in trends between these groups. However, diabetes was associated with añ 3.5-to 5-fold risk of CVD events. In-hospital mortality rates declined for AMI and stroke, remained unchanged for CABG, and increased for PCI admissions in both groups.
T he incidence and mortality from cardiovascular disease (CVD) have declined markedly during the last several decades in the U.K. and other Western societies (1-3). Advances in understanding and control of major cardiovascular risk factors and medical care of CVD have contributed to these reductions (4) . However, although previous reports from different populations and study settings have emphasized favorable trends in adults without diabetes, conflicting findings were reported in people with diabetes.
Some data indicate similar reductions in CVD rates in these groups, whereas other data report that adults with diabetes had lower declines in their CVD event rates compared with the improvement experienced by people without diabetes (5) (6) (7) (8) . Some studies found no evidence that people with diabetes, particularly women, benefited from the reductions in CVD incidence (7, 9) . In the U.K., the considerable recent increases in obesity and diabetes, particularly among young and middle-aged adults, could increase CVD rates (10). A study showed increased coronary heart disease (CHD) mortality rates in young men in 2002 in England and Wales and explained this finding by adverse trends in CHD risk factors (11) .
As part of a national strategy to reduce CVD mortality, a number of qualityimprovement initiatives were introduced in the U.K. health system during the last decade, with a major emphasis on secondary prevention (12) (13) (14) . However, there are no data available on whether these reforms have had a significant effect on the clinical outcomes of diabetes, such as cardiovascular events.
Although CVD remains the leading cause of death and hospitalization for CVD is one of the main users of health resources, data on recent national trends in CVD among people with and without diabetes in England are lacking. The objective of this study was to describe the trends in the rate of major cardiovascular events requiring hospital admission (myocardial infarction [MI] , angina, and stroke) and cardiovascular interventions (percutaneous coronary intervention [PCI] and coronary artery bypass graft [CABG] ) among people with and without diabetes between 2004 and 2009 in England. We also aimed to describe the relative risk of these events in people with diabetes. The dataset covers all inpatient hospital activity and day case admissions to NHS (public) hospitals across England, including private patients treated in NHS hospitals. Data extracted for each hospital admission included patient demographics (age and sex), in-hospital mortality, length of hospital stay (LOS), principal diagnosis, and up to 13 secondary diagnoses coded using the ICD-10. Interventions were defined using the Office of Population Censuses and Surveys' Classification of Surgical Operations (OPCS4) codes in up to 12 procedure fields. Diabetes status was based on type 1 or type 2 diabetes, ICD-10 codes E10 and E11, recorded in any diagnosis field.
RESEARCH DESIGN AND
Cardiovascular complications, identified as the principal or primary diagnosis on admission, were acute MI (AMI; ICD-10 I21 and I22), angina (ICD-10 I20), and stroke (ICD-10 I60-I64). Cardiovascular interventions were identified using procedure codes for PCI (OPCS4 K49, K50, and K75) or CABG (OPCS4 K40-K46) in any procedure field. We used a combination of date of birth, sex, and full postcode to distinguish patients.
To assess comorbidity in the population, the Charlson Comorbidity Index was used, derived from ICD-10 diagnoses (15) . The index is based on a number of medical conditions, each with original weights ranging from 1 to 6; we derived England-specific weights ranging from 21 to +18. Higher scores represent a greater burden of comorbidity.
Admission rates in people with diabetes were calculated for each year using the total number of admissions for CVD as the numerator and the total number of people with diabetes in England as the denominator. Data on the number of people aged .16 years who were diagnosed with diabetes in England were obtained from the Quality Management and Analysis System (QMAS) for each study year (14) . The QMAS is the financial database for the Quality and Outcomes Framework (QOF) and contains diabetes counts and prevalence data for virtually all (.99%) general practices in England. Because the QMAS does not hold information on the age and sex distribution of the population with diabetes, we obtained this information from the Health Survey for England 2006 (10). When calculating age-and sex-specific rates, we assumed that the age and sex distribution of the population with diabetes remained con- , when diabetes figures were available for the total population, we calculated diabetes prevalence for patients aged .16 years for both years, using the age-and sex-standardized diabetes prevalence in children and young adults (16) . This enabled us to calculate age-and sex-specific admission rates for each event and intervention for each year during the study period. The estimated resident population of England was used to calculate the admission rate of CVD events in people without diabetes for each year (17). The number of people with diabetes was deducted from each corresponding age and sex stratum of the total population. Therefore, the denominator for people without diabetes did not include the total population (both people with and without diabetes), only the number of people without diabetes. Rates were expressed per 100,000 people with or without diabetes.
To test time trends in CVD rates, we fitted separate Poisson regression models for patients with and without diabetes, using age, sex, and year as independent variables. Interactions between sex and year and between age and year were tested, and Poisson models were fitted for sex and age subgroups if P , 0.05 for the interactions. We estimated the risk of a person with diabetes being admitted to the hospital for CVD compared with a person without diabetes. Statistical analyses were performed using Stata (College Station, TX). There was a considerable male excess of CVD admissions overall in both groups, except for stroke, among people without diabetes (Table 1 ). This male predominance was most pronounced for cardiovascular interventions in both individuals with and without diabetes. Most CVD events occurred in individuals aged $65 years, with a significantly higher proportion in people with diabetes (P , 0.001 for all), except for CABG (P = 0.17). In 2009, the median LOS was significantly lower for all admissions in both groups compared with 2004. However, the size of this decrease was small for cardiovascular procedures. The mean Charlson Comorbidity Index score was significantly higher in 2009 in both groups for all admissions compared with 2004 (Table 1) .
In-hospital mortality rates Changes in in-hospital mortality rates showed similar patterns in people with and without diabetes, with a significant decline for AMI and stroke, increased rates for PCI, and unchanged rates for CABG admissions (Table 1 ). For angina admissions, there was a significant decline in mortality rates in people without diabetes, whereas rates in patients with diabetes did not significantly change. Table 2) . PCI rates in people with diabetes increased significantly, and the incidence of stroke did not significantly change. Over the study period, people without diabetes experienced similar proportional changes for all CVD outcomes as those with diabetes, with no statistically significant differences in trends between these groups ( Table 2) .
Changes in admission rates
The trend in stroke admissions in individuals with diabetes varied by sex, but this was not evident for other outcomes (Fig. 1A ). In women with diabetes, there was a significant decline in admissions for stroke (rate ratio 0.99 per year [95% CI 0.97-0.99]; P = 0.005), whereas there was a nonsignificant increase in rates in men (1.00 per year [0.99-1.01]; P = 0.47).
When examining trends across different age-groups, significant variations were found in people with diabetes for angina admissions and PCI (Fig. 1B) . With regard to angina, a similar but more pronounced decline was seen among older subjects with diabetes (aged $65 years: 
Relative risk
People with diabetes were approximately five times more likely to be admitted for angina, AMI, and CABG; four times more likely to undergo a PCI; and three and a half times more likely to be admitted for a stroke than those without diabetes (Table 3) . These figures did not However, people with diabetes continue to remain at~3.5-to 5-fold higher risk of hospitalization for major CVD events and interventions than people without diabetes.
In-hospital mortality rates declined significantly for AMI and stroke, remained unchanged for CABG, and increased for PCI admissions in both individuals with and without diabetes.
Since the late 1970s, there have been marked reductions in CVD event and mortality rates in most industrialized countries (1,3,4) . However, these improvements attenuated during the 1990s among adults aged ,55 years compared with previous trends (11, 18) . When examining population subgroups, one study showed reversed trends in CHD mortality rates in young men aged 35-44 years in the U.K. during the 1990s (11) . Some studies suggested that the benefits of population changes in CVD rates might not be shared equally among people with and without diabetes, and diabetes might be a major contributor to the slowdown of improvement seen in the population (7, 9) . Although it is important to understand whether people with and without diabetes are affected differently by CVD, there is little information on recent trends in CVD rates in people with and without diabetes in England. The majority of previous studies have not reported diabetesspecific CVD outcome rates because of the lack of accurate information on diabetes prevalence (11, 19, 20) . The results of cohort or local studies also might not reflect national trends (6, 21) . This is the first study we are aware of that identifies recent admission rates for major CVD events in people with diabetes using a national sample that covers the entire population of England.
Numerous factors could explain the favorable trends in hospital admissions for acute coronary syndrome and intervention rates over the study period. The prevention and treatment of CVD and its risk factors have assumed increasing importance in U.K. health policy during the last decade (12, 14) . The U.K. government has made considerable investments in health services and introduced a wide range of initiatives, including national treatment standards for the management of major chronic conditions with a special focus on secondary prevention (14, 22) . The introduction of the QOF, a major pay-for-performance program in 2004, was associated with accelerated improvements in CVD risk factors, including blood pressure and cholesterol control in people with diabetes (14) . Favorable trends in cigarette smoking, physical activity levels, and increased use of ACE inhibitors and antihypertensive and lipidlowering medications also might have contributed to these changes (10). Furthermore, better treatment of CVD itself also could have translated into reductions in admission and readmission rates for CVD (4).
Our results correspond with studies reporting similar reductions in CVD rates among people with and without diabetes (5, 6, 21) . Some earlier studies found smaller improvement in CVD events in those with diabetes (7, 9, 23) . There are several potential explanations for this discrepancy beyond differences in study design and case definition. People with diabetes often were less likely to receive intensive treatment for their CVD and CVD risk factors and were less likely to undergo therapeutic interventions compared with those without diabetes (24, 25) . For example, several studies demonstrated that people with diabetes presenting with an AMI were less likely to receive evidence-based treatments, including b-blockers, aspirin, thrombolysis, and revascularization procedures compared with those without diabetes (24, 25) . Furthermore, the intensity of the management showed inverse association with increasing cardiovascular risk, further disadvantaging older individuals and those with more comorbidities (24, 26) . Hence, the higher baseline cardiovascular risk was compounded by a suboptimal treatment of the condition and its risk factors in individuals with diabetes. In previous studies, the lower level of improvement in CVD outcomes in people with diabetes may have partly followed from these disparities. Our results might reflect changes in historical patterns of care in England. People with diabetes now get more aggressive management for their condition than during previous years as a result of increased awareness of diabetes and various nationwide targeted interventions (14, 27) . This is supported by a number of recent studies showing substantial improvement in diabetes management and cardiovascular risk factor control in U.K. primary care as a result of targeted interventions (14, 27, 28) . Recent studies from the U.K. show that people with diabetes with a higher number of comorbid conditions receive more intensive treatment and are more likely to achieve established treatment targets compared with counterparts with less comorbidities, which indicate changes in previous patterns Rates are expressed as 100,000 people with diabetes. Trends were tested separately for men and women and different age-groups if P , 0.05 for the sex-year or age-group-year interaction.
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As in other studies, we found that PCI rates increased significantly, whereas CABG rates declined, during the study period (30, 31) . Changes in practice patterns could be attributable to CABG being the more invasive procedure and advances in PCI such as the introduction of drug-eluting stents and considerable improvements in the short-and long-term outcomes of PCI, among other factors (32) . Despite substantial evidence that for patients with severe forms of CHD, particularly patients with diabetes, CABG offers advantages in terms of survival and need for repeat revascularization, we found a similar shift from CABG to PCI in people with diabetes as in individuals without diabetes. The increases in in-hospital mortality rates for PCI, despite technological advances in interventional techniques and improvements in periprocedural care, might be attributable to the increasing complexity of cases referred for PCI.
We found similar proportional changes in admission rates for AMI, stroke, and CABG in elderly when compared with younger individuals with diabetes. The overall increase in PCI rates in people with diabetes could largely be explained by the expansion of PCI in the elderly. Furthermore, people aged $75 years with diabetes experienced a larger annual decline in admission rates for angina than younger patients. These findings might reflect more aggressive treatment applied in higherrisk patients compared with previous years, as earlier studies described inverse associations between treatment propensity and age. A recent study showed largely attenuating differences in the measurement and achievement of established treatment targets between elderly patients aged $75 years and younger individuals with diabetes after the introduction of the QOF (27) .
Our observation of stable admission rates of stroke in people with and without diabetes differs from earlier studies (5, 33) . However, it is difficult to make direct comparisons, because most studies did not report trends by diabetes status, had considerably longer follow-up time, were conducted a long time ago, or reported rates from small geographic areas (34, 35) . There are limited data on temporal changes in stroke incidence from the U.K. A recent systematic review only could identify one article reporting trends in stroke incidence in the U.K., which showed a decline in south London over the period of 1995-2004 (35) . A local study reported a decrease in the number and incidence of major stroke in Oxfordshire between 1981 and 2004 (34) . The reason of the significant decline found in women but not in men with diabetes is unclear. The World Health Organization MONICA (Multinational Monitoring of Trends and Determinants in Cardiovascular Disease) project showed decreased stroke rates among men in 13 populations and among women in 15 of 17 MONICA populations in 1997. However, this study did not report stroke rates for people with and without diabetes, and the number of populations with statistically significant trends were small (33) . It is possible that the larger recent improvements in blood pressure and cholesterol control in women with diabetes since the introduction of the QOF, particularly in the elderly, could partly explain our finding (27) .
Our national study used a sample that covers the entire population of England and therefore is likely to provide an accurate reflection on population changes in CVD rates. Previous studies are limited by the lack of available or accurate data on diabetes prevalence. By contrast, the diabetes denominator for our study was derived from a national database. Given that~99% of the U.K. population is registered with a general practitioner, and nearly all practices participate in the pay-for-performance program that financially incentivizes disease registers, our estimations likely are to be robust (14) .
Limitations of our study need to be considered when interpreting our results. Although concerns about the accuracy of routinely collected datasets have been raised, these data are continuously audited, and the quality and validity of this dataset has been assessed and proved useful for health research (19, 36, 37) . A systematic review of discharge coding evaluated it as high, especially for operations and procedures (36) . Better ascertainment and recording of diabetes after the implementation of the QOF might explain some of the increase in diabetes prevalence during the study period, because general practices are financially incentivized to identify and report all diabetes cases. However, the increase was consistent during the study period, and most of the improved ascertainment likely is to have occurred immediately before the study period as practices responded to the incentives in the QOF. Furthermore, the increase in the mean Charlson Comorbidity Index score, which would indicate the admission of more complex cases for CVD, is likely to also reflect better coding of less common comorbid conditions on hospital records since the introduction of payment by results, a new payment regimen for hospitals introduced in 2005-2006 (38). We did not distinguish between type 1 and type 2 diabetes because separate data on national prevalence were not available.
Our data provide recent national information on changes in the burden of CVD events across England. Our results show a considerable recent decline in admissions for angina, AMI, and CABG; unchanged stroke rates; and increasing PCI rates in people with and without diabetes. However, despite significant declines, people with diabetes still are at an~3.5-to 5-fold risk of CVD events compared with those without diabetes. Furthermore, the absolute population burden of CVD is expected to further rise, given the rapidly increasing prevalence of diabetes and the aging population. Hence, these findings emphasize the ongoing need for aggressive risk reduction and primary prevention of CVD in people with diabetes.
